AlloVir Future Growth

NasdaqGS:ALVR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-54	N/A	N/A	1
12/31/2025	N/A	-41	N/A	N/A	2
12/31/2024	N/A	-42	-45	-45	3
12/31/2023	N/A	-190	-124	-124	N/A
9/30/2023	N/A	-169	-125	-125	N/A
6/30/2023	N/A	-167	-126	-126	N/A
3/31/2023	N/A	-166	-128	-128	N/A
12/31/2022	N/A	-169	-142	-142	N/A
9/30/2022	N/A	-189	-138	-139	N/A
6/30/2022	N/A	-192	-140	-140	N/A
3/31/2022	N/A	-185	-134	-134	N/A
12/31/2021	N/A	-172	-106	-106	N/A
9/30/2021	N/A	-139	-100	-99	N/A
6/30/2021	N/A	-117	-82	-81	N/A
3/31/2021	N/A	-91	-70	-69	N/A
12/31/2020	N/A	-70	-61	-61	N/A
9/30/2020	N/A	-53	-49	-49	N/A
6/30/2020	N/A	-37	-37	-37	N/A
3/31/2020	N/A	-31	-29	-29	N/A
12/31/2019	0	-24	-20	-20	N/A
12/31/2018	1	-8	2	2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALVR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALVR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALVR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALVR's revenue is forecast to grow faster than the US market.

AlloVir Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 71% to US$5.63

Price target decreased by 7.6% to US$21.25

Price target decreased by 13% to US$23.00

Price target decreased to US$27.50

Price target decreased to US$32.00

Price target decreased to US$38.75

Recent updates

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 3000E Value Index

Chief Scientific Officer recently sold US$3.4m worth of stock

AlloVir EPS misses by $0.08

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

New 90-day low: US$34.53